Submission & Approval

Biologics License Application(BLA)

A submission to the FDA requesting approval to market a biological product in the United States.

Usage Examples

The company filed a BLA for their CAR-T cell therapy.
FDA granted priority review for the BLA based on breakthrough therapy designation.
The BLA included manufacturing data from three production facilities.

What is BLA?

A Biologics License Application (BLA) is the submission required for FDA approval to market biological products, including vaccines, blood products, gene therapies, cellular therapies, and therapeutic proteins.

Unlike chemically synthesized drugs covered by NDAs, biological products are derived from living organisms and require specialized manufacturing and quality controls. BLAs are reviewed by the Center for Biologics Evaluation and Research (CBER) or the Center for Drug Evaluation and Research (CDER), depending on the product type.

The BLA must demonstrate the product's safety, purity, and potency through comprehensive preclinical and clinical data, as well as detailed information about manufacturing processes and facility compliance.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 601, 42 USC 262.

FDAICHEMA

When This Matters

The company filed a BLA for their CAR-T cell therapy.
FDA granted priority review for the BLA based on breakthrough therapy designation.
The BLA included manufacturing data from three production facilities.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

21 CFR 60142 USC 262

Frequently Asked Questions

BLAs are for biological products derived from living sources (vaccines, blood products, gene therapies), while NDAs are for chemically synthesized drugs. BLAs have additional requirements for demonstrating product consistency due to the complexity of biological manufacturing.

CBER reviews most traditional biologics (vaccines, blood products, gene therapies), while CDER reviews therapeutic proteins and monoclonal antibodies transferred from CBER.

A biosimilar BLA (351(k) application) is for products highly similar to an already-approved biological reference product, with no clinically meaningful differences in safety, purity, or potency.